Reimbursement pharmaco-economic assessment
"Mediconomics" combines "Medicine" and "Economics"
Mediconomics is keenly updated with laws in health economics in the European and US regions, especially in the areas of Health Technology Assessments (HTA) and Outcomes Research. It goes without saying that we comply with the German Social Code, Book Five (SGB V), section 35a in conjunction with the Act on the Reform of the Market for Medicinal Products (AMNOG). We evaluate potential risks in pricing and reimbursement, budget optimization and ultimately support reimbursement decisions.
We support you to develop good practices for your own-value-based pricing systems and help to generate information on revenue generated as the value of your product. Our expertise guides you towards improvement of access to the Orphan Drug Market in a particular European countries and the US.
Mediconomics supports your route towards optimal use of resources for a sustainable investment in financing development. We evaluate risk-sharing and conditional pricing of your medicinal product and appropriately guide you from start until your launch of your products! Our friendly, international and multilingual team works on the philosophy of support in a fast, reliable and economic way. Mediconomics is a problem-solver for your financial questions in Market Research and Market Access.